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Abstract
The ICF syndrome is a rare autosomal recessive disorder, the most common symptoms of which are immunodeficiency,
facial anomalies and cytogenetic defects involving decondensation and instability of chromosome 1, 9 and 16 centromeric
regions. ICF is also characterised by significant hypomethylation of the classical satellite DNA, the major constituent of the
juxtacentromeric heterochromatin. Here we report the first attempt at analysing some of the defining genetic and
epigenetic changes of this syndrome from a nuclear architecture perspective. In particular, we have compared in ICF (Type 1
and Type 2) and controls the large-scale organisation of chromosome 1 and 16 juxtacentromeric heterochromatic regions,
their intra-nuclear positioning, and co-localisation with five specific genes (BTG2, CNN3, ID3, RGS1, F13A1), on which we have
concurrently conducted expression and methylation analysis. Our investigations, carried out by a combination of molecular
and cytological techniques, demonstrate the existence of specific and quantifiable differences in the genomic and nuclear
organisation of the juxtacentromeric heterochromatin in ICF. DNA hypomethylation, previously reported to correlate with
the decondensation of centromeric regions in metaphase described in these patients, appears also to correlate with the
heterochromatin spatial configuration in interphase. Finally, our findings on the relative positioning of hypomethylated
satellite sequences and abnormally expressed genes suggest a connection between disruption of long-range gene-
heterochromatin associations and some of the changes in gene expression in ICF. Beyond its relevance to the ICF syndrome,
by addressing fundamental principles of chromosome functional organisation within the cell nucleus, this work aims to
contribute to the current debate on the epigenetic impact of nuclear architecture in development and disease.
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Introduction
The Immunodeficiency, Centromeric region instability and
Facial anomalies (ICF) syndrome (OMIM 242860) is a rare
autosomal recessive disorder often fatal in childhood [1]. So far,
less than 50 cases have been reported worldwide.
The ICF syndrome is characterised by phenotypic and clinical
variability, with the most consistent features being reduction in
serum immunoglobulin (Ig) levels, developmental delay, facial
anomalies and cytogenetic defects. The normal cause of death in
ICF patients is infection, usually of the pulmonary or gastrointes-
tinal tract [rev. in [2]].
Cytogenetic defects of diagnostic significance principally involve
decondensation of the juxtacentromeric (or centromere adjacent)
heterochromatic regions of chromosomes 1 and 16, and to a lesser
extent chromosome 9. In mitogen-stimulated lymphocytes, a wide
array of aberrations can be observed, ranging from greatly
stretched heterochromatic regions to multiradiate chromosomes.
The juxtacentromeric heterochromatic regions of chromosome 1
and 16 are mainly comprised of classical satellite 2 and 3 repeats.
Chromosome fusion in the ICF syndrome occurs only at regions of
decondensed centromere-adjacent heterochromatin, and the alpha
satellite repeats, the main component of centromeres, always
remain outside the regions of multiradiate chromosome fusions
[3,4]. Lymphoblastoid cell lines generated from ICF patients also
show high frequencies of the same karyotypic abnormalities as
those observed in mitogen-stimulated lymphocytes [5,6].
ICF syndrome is also characterised by abnormal DNA
methylation. Although only a slight decrease in 5-methylcytosine
has been observed at the overall genomic level [7], the classical
satellite 2 DNA sequences are significantly and consistently
hypomethylated at cytosine residues in this syndrome [3,8,9,10].
Chromosome 9 juxtacentromeric heterochromatin, which mainly
consists of related satellite 3 DNA is also hypomethylated,
although to a lesser extent [9,11]. A small number of other
genomic regions show significant hypomethylation in ICF
syndrome, most notably the non-satellite repeats D4Z4 and
NBL2 [10]. Single copy loci showing heterogeneous hypomethyla-
tion comprise SCP-1 [12], the imprinted loci D15S9, D15S63 and
H19 [3] and in female ICF cells a number of genes residing on the
inactive X chromosome [3,12,13]. Also, some significant changes
in DNA methylation patterns at promoters and CpG rich regions
were recently identified within a sample of dysregulated genes in
ICF [14].
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 ICF syndrome was initially linked to chromosome 20q11.2 [15]
and subsequently the DNA methyltransferase 3B gene (DNMT3B)
was identified as the gene responsible for the methylation defects
observed in ICF [7]. Along with DNMT3A, DNMT3B acts to
methylate cytosine residues de novo and is essential for normal
development [16].
Mutations of DNMT3B in ICF syndrome are heterogeneous.
Analysis of fourteen patients revealed eleven different mutations,
including eight different missense mutations, two nonsense
mutations and a splice site mutation [17]. Nonsense mutations
always occur as compound heterozygous, highlighting that the
DNMT3B protein is essential for life. Most recently, a model for
ICF syndrome has been engineered by generating Dnmt3b
mutations in mice [18]. Homozygous mice carrying two missense
alleles of Dnmt3b show many ICF-like characteristics, including
hypomethylation of heterochromatin repeat DNA.
Wijmenga and collaborators [17] also identified five ICF
patients who do not carry mutations in the DNMT3B gene. More
recent investigations described further patients who did not carry a
mutation of DNMT3B [19,20]. Intriguingly, Jiang and co-authors
showed that the subset of patients carrying a mutation in the
DNMT3B gene had alpha satellite methylation patterns compara-
ble to control samples. In contrast, the subset of patients who did
not carry mutations in DNMT3B exhibited hypomethylation of the
alpha satellite as well as classical satellite DNA. These findings lead
to the proposal of the existence of two distinct types of ICF
syndrome, namely a Type 1, in which patients display mutations
in the DNMT3B gene, but have normal alpha satellite methylation,
and a Type 2, characterised by normal DNMT3B and hypo-
methylation of alpha satellite DNA [19].
Global expression studies by microarray analysis have identified
significant changes in the expression of several hundreds of genes
in ICF, involved in immune function, development and neuro-
genesis as well as lymphogenesis, signal transduction and apoptosis
[14,21].
Over the years, several hypotheses linking altered gene
expression to the hypomethylation of juxtacentromeric hetero-
chromatin in ICF have been postulated by different research
groups, commonly suggesting inappropriate release or recruitment
of regulatory complexes by the hypomethylated satellite DNA,
affecting the regulatory properties of the heterochromatin
[7,8,13,21,22].
These suggestions have prompted us to investigate whether the
decondensation of the juxtacentromeric heterochromatin, as
observed in metaphase, and general chromosomal instability
reported in ICF patients, correspond to changes in the three-
dimensional properties of the heterochromatin in interphase; our
working hypothesis being that disruption to the heterochromatin
spatial configuration may interfere with transcriptional silencing
and be indirectly responsible for some of the changes in gene
expression accounting for the symptoms of ICF.
Accordingly, we have analysed and compared in two patients
(ICF Type 1 and ICF Type 2) and both related (unaffected
parents) and unrelated controls the large-scale organisation and
intra-nuclear positioning of chromosome 1 and 16 juxtacentro-
meric heterochromatin. Heterochromatin organisation and posi-
tioning have been analysed in different cell lines and cultures,
including, as well as ICF cells presenting different degrees of
classical satellite 2 hypomethylation [8], control cells in which
DNA hypomethylation had been experimentally induced by
treatment with 5-azacytidine. We have also carried out a
comparative quantification of chromosome 1 satellite 2 and 3
repeats in ICF cells and controls. Finally, we have analysed and
compared the intra-nuclear positioning of four genes from
chromosome 1 and one gene from chromosome 6 – namely
BTG2 (B-cell translocation gene 2) (1q32), CNN3 (Calponin 3)
(1p22-p21), ID3 (Inhibitor of DNA binding 3)(1p36.13-p36.12),
RGS1 (Regulator of G protein signalling) (1q31) and F13A1 (Factor
XIII; A1 subunit) (6p25-p24) - and their co-localisation with the
juxtacentromeric heterochromatin of chromosome 1. The expres-
sion of these genes had previously been reported to be altered in
ICF [21]. We have assessed and compared their expression levels
in our patients and control cell lines, and, for three of them, we
have also analysed in detail the methylation status of upstream
CpG islands of their promoters using a quantitative methylation
assay.
Beyond its relevance to the ICF syndrome, by addressing
fundamental principles of chromosome functional organisation
within the cell nucleus, this work aims to contribute to the current
debate on the epigenetic impact of nuclear architecture in
development and disease.
Results
The large-scale organisation of chromosome 1
juxtacentromeric heterochromatin is altered in ICF B-cells
Observations on the heterochromatin in interphase, conducted
in parallel by wide-field and confocal microscopy, revealed some
significant differences between ICF cells and controls. Chromo-
some 1 juxtacentromeric heterochromatin, as defined by hybrid-
isation with the classical satellite DNA probe D1Z1, and
chromosome 16 juxtacentromeric heterochromatin, as defined
by hybridisation with the classical satellite DNA probe D16Z3,
were analysed and compared in B-lymphoblastoid cell nuclei of
two different patients (ICF Patient 1 presenting with ICF Type 1
and ICF Patient 2 presenting with ICF Type 2) and three controls,
two of which were unaffected parents of the ICF patients
(respectively called Control 1 and Control 2) and one a normal
unrelated B-lymphoblastoid cell line (DO208915). Evaluation of
the fluorescent hybridisation signals on a per cell basis on 2D fixed
cells (2D FISH) allowed us to identify in each cell population the
co-existence of noticeably different hybridisation patterns (Exam-
ples in Fig. 1).
In order to quantify possible cumulative differences in the large-
scale organisation of the heterochromatin of chromosome 1 in ICF
B-cells and controls, we measured the intra-nuclear areas occupied
by the juxtacentromeric heterochromatic regions, as defined by
hybridisation on 2D-fixed interphase nuclei with the correspond-
ing classical satellite DNA probe (Fig. 2). The measurements were
performed as described in the Materials and Methods. The data
sets were compared using a Kolmogorov-Smirnov test, which
revealed a statistically significant difference between ICF and
Control cells (D=0.3480, P,0.001).
Similar to that observed for chromosome 1, when measure-
ments of the hybridisation areas of chromosome 16 juxtacen-
tromeric heterochromatin were obtained and averaged, this
heterochromatic region appeared to be smaller in ICF nuclei
compared to controls (Fig. 3). However, when the data sets were
compared, no statistically significant difference was observed
between ICF and Control (D=0.1029, P=0.076).
To further corroborate the results obtained by 2D FISH, the
large-scale organisation of chromosome 1 juxtacentromeric
heterochromatin was also investigated and compared in ICF
Patient 1 and Control 1 by means of 3D FISH, a variant of the
hybridisation technique believed to better preserve nuclear
architecture, followed by laser scanning confocal microscopy
analysis (Fig. 4). Volume measurements were carried out as
described in the Materials and Methods. The heterochromatin
Nuclear Organisation in ICF
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with a mean value of 0.970 mm
3 (SD=0.37) (N=202), whilst in
the Control the mean value was 1.147 mm
3 (SD=0.53) (N=147).
The data sets were compared using a Kolmogorov-Smirnov test,
which revealed a statistically significant difference between the
ICF and Control volume distributions (D=0.2356, P,0.001).
Contrary to the consensual view that decondensation and
stretching of the juxtacentromeric heterochromatic regions, as
generally observed in metaphase in ICF, should be expected to
correspond to decondensation and stretching in interphase, our
findings on the large-scale organisation of these chromosomal
land-marks in B-cells show that the ICF nuclear phenotype – when
compared to controls - is characterised by an apparently
more compact spatial configuration of the juxtacentromeric
heterochromatin.
Variability of chromosome 1 juxtacentromeric
heterochromatin organisation in interphase is not cell-
cycle related
In order to establish whether the variability in the configuration of
chromosome 1 juxtacentromeric heterochromatin, observed between
and within cell cultures, could be related to dissimilarities in the rate
of proliferation and progression through the cell-cycle between ICF
cells and controls, we conducted some comparative tests to assess the
existence of a temporal connection between the different hetero-
chromatin patterns and specific stages of the cell-cycle.
First, we investigated possible cell cycle stage composition
differences between ICF and control cell lines by FACS analysis
(Figure S1).These investigations revealed very similar percentages
of diploid cells in G1, S and G2 for the ICF Patient 1 and Control
1, and for the ICF Patient 2 and Control 2 samples analysed,
ruling out significant differences in cell cycle stage composition
between the patient and control cell lines.
Then, we hybridised chromosome 1 classical satellite probe D1Z1
to BrdU pulse-labelled B-lymphoblastoid cells from ICF Patient 1
and Control 1 (Fig. 5). Cells undergoing DNA replication (S-phase)
were visualised by antibody detection of incorporated BrdU. The
different immunolabelling patterns were interpreted according to
O’Keefe et al. [23]. The ‘‘conventional‘‘ (Fig. 5A) and ‘‘compact’’
(Fig. 5B) heterochromatin patterns appeared to be present
indiscriminately during S phase progression and non-S phase of
the cell cycle in both Control 1 (N=91) and ICF Patient 1 (N=70).
Based on both our FACS analysis and our BrdU incorporation
experiments, we conclude that proliferation status and progression
through cell-cycle can be excluded as factors responsible for the
variability in the spatial configuration of juxtacentromeric
heterochromatin observed between and within cell populations.
The intra-nuclear positioning of chromosome 1
juxtacentromeric heterochromatin is also altered in ICF B-
cells
The positioning of chromosomes 1 and 16 juxtacentromeric
heterochromatin in interphase was also assessed and compared in
B-lymphoblastoid cells from ICF patients and controls. Preliminary
observationswereaimed atestablishingwhetherchromosome1 and
chromosome 16 centromeric regions showed preferential associa-
tion with the extreme nuclear periphery, and identifying possible
differencesbetween patientsand controls.Preferentialpositioningof
chromosome 1 juxtacentromeric heterochromatin at the nuclear
periphery was assessed in ICF Patient 1 and 2, Control 1 and 2, and
DO208915.The heterochromatic signal was considered to be
positioned at the extreme nuclear periphery when any part of it
appearedto associate withthe nuclear rim, as defined by the edge of
the DAPI staining (Examples in Fig. 6). These observations were
conducted independently from any consideration on the hetero-
chromatin configuration, and a minimum of 100 nuclei for each
experiment were scored randomly.
Our observations on control B-cells showed no marked
preferential positioning at the extreme nuclear periphery for
chromosome 1 juxtacentromeric heterochromatin, with less than
25% of D1Z1 signals normally associating with the nuclear rim in
all cell lines analysed (Fig. 6A). Interestingly, in ICF B-cell nuclei,
juxtacentromeric heterochromatin positioning at the extreme
nuclear periphery was less frequent, with the percentage of
D1Z1 signals associating with the nuclear rim being less than 15%
in all cells cultures analysed. The reduction in association of the
D1Z1 hybridisation signal with the extreme nuclear periphery in
ICF B-cell lines compared to controls is statistically significant
using a Chi-squared goodness of fit test (x
2=4.882, P=0.027).
Similar observations on the intranuclear positioning of chro-
mosome 16 juxtacentromeric heterochromatin were conducted on
ICF Patient 1 and 2, Control 1 and 2, and DO208915 (Fig. 6B). As
observed for chromosome 1, there was no evidence of preferential
positioning of chromosome 16 juxtacentromeric heterochromatin
at the extreme nuclear periphery in either ICF or control nuclei,
but the reduction in association of the heterochromatin with the
extreme nuclear periphery observed between ICF and control cell
lines proved to be statistically significant (x
2=10.563, P=0.001).
Figure 1. Visualisation of the juxtacentromeric heterochroma-
tin in the cell nucleus. Chromosome 1 and chromosome 16
juxtacentromeric heterochromatic regions were visualised by hybridis-
ing to interphase nuclei (counterstained with DAPI) (blue) the classical
satellite DNA probes D1Z1 (red) and D16Z3 (green), respectively.
Evaluation of the hybridisation signals on a cell-by-cell basis allowed the
identification of a pronounced inter-nuclear and inter-allelic variability
in the heterochromatin patterns within each of the cell populations
(either patients or controls). Above are examples of two easily
distinguishable configurations: ‘‘conventional’’ (the fluorescent signal
is typically conspicuous and its outline is uneven) (A and B) and
‘‘compact’’ (the fluorescent signal is conspicuously smaller and its
outline well defined) (C and D). Single channel images were imaged
using a monochrome CCD camera attached to a wide-field fluorescence
microscope, pseudocoloured and merged. Insert boxes within each
image show the heterochromatic signal digitally enhanced.
doi:10.1371/journal.pone.0011364.g001
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intra-nuclear positioning between ICF and controls, the distance
from the centroid of each juxtacentromeric heterochromatin signal
to the nuclear rim was measured as described in Materials and
Methods, and averaged in each cell line. To obtain the mean
distance of D1Z1 from the extreme nuclear periphery, measure-
ments from two independent experiments were carried out for
each cell line (Fig. 7). To take into consideration the varying sizes
of nuclei, the measurements were normalised. When performing a
Kolmogorov-Smirnov test, the distance of chromosome 1
juxtacentromeric heterochromatin from the nuclear periphery
was significantly greater in ICF cell lines when compared to
control cell lines (D=0.1405, P,0.001).
The distance of the D16Z3 signal from the extreme nuclear
periphery was also measured in B-lymphoblastoid interphase cells
from ICF Patient 1 and 2, Control 1 and 2 and DO208915 (Fig. 8).
As for chromosome 1, the different sizes of nuclei were taken into
consideration by calculating the ratios between distance from
nuclear periphery and nuclear radius. However, in contrast to
previous observations, there was no significant difference in the
distance of D16Z3 to the nuclear periphery between ICF and
normal cell lines (D=0.0558, P=0.678).
In ICF B-cells, when compared to controls, the degree of
association of the hypomethylated chromosome 1 classical satellite
DNA signals with the nuclear periphery is lower, suggesting a
specific re-positioning of the juxtacentromeric heterochromatin to
a more internal location within the nuclear volume.
Changes in the heterochromatin configuration, as
observed in ICF nuclei, can be partially replicated in
control cells by treatment with a demethylating agent
It was previously shown that it is possible to reproduce in normal
lymphoblastoid celllines many of the cytological anomalies observed
at metaphase in ICF syndrome, in particular the high frequency of
juxtacentromeric rearrangements of chromosome 1, by treatment
Figure 2. Chromosome 1 juxtacentromeric heterochromatin: area measurements in ICF cells and controls. Measurements of the areas
occupied by chromosome 1 juxtacentromeric heterochromatin, as defined by hybridisation with the D1Z1 classical satellite DNA probe, were carried
out in hundreds of 2D-fixed interphase nuclei for each cell line and the mean values calculated. The measurements were performed as described in
the Materials and Methods. The data sets were compared using a Kolmogorov-Smirnov test, which revealed a statistically significant difference
between ICF patients and Controls altogether (D=0.3480, P,0.001).
doi:10.1371/journal.pone.0011364.g002
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azadeoxycytidine [24,25,26]. In order to investigate whether
treatment with a demethylating agent was also able to reproduce
innormal cells thechangesto thelarge-scaleorganisation andspatial
positioning of the heterochromatin observed by us in interphase in
this syndrome, we conducted further observations on our cell lines
after treatment with 5-azacytidine.
We first established the effect of the demethylating treatment on
metaphase chromosomes by incubating unsynchronised B-lym-
phoblastoid cell lines from Control 1 and 2 with 5-azacytidine for
18 hours, following the protocol previously described by Ji et al.
[25]. We compared metaphase spreads from the 5-azacytidine
treated and non-treated cultures and, we observed that following
the 5-azacytidine treatment, the otherwise normal control cells
displayed decondensation of the chromosome 1 juxtacentromeric
region in 10–15% of metaphases analysed (Figure S2 and Figure
S3). We also carried out an immunostaining test with a
monoclonal antibody against 5-Methylcytidine to detect changes
in the chromosomal methylation patterns, with particular focus on
the chromosome 1 heterochromatin. We observed that, following
the 18 hour treatment with 5-azacytidine, there was a significant
intercellular variability in terms of extent and distribution of DNA
methylation, with some metaphases and nuclei showing almost no
methylation at all and others showing still substantial methylation,
particularly on the compact heterochromatic areas. However,
most importantly, the stretched or decondensed juxtacentromeric
heterochromatin appeared to be consistently demethylated (Fig. 9).
We then proceeded with observations on the chromosome 1
juxtacentromeric heterochromatin configuration in interphase and
comparative assessments of the heterochromatin areas in ICF
Patient 1 and 2, Control 1 and 2 and DO208915 B-lymphoblas-
toid cells before and after treatment with 5-azacytidine. Measure-
ments were performed as described previously (Table 1). In the
Kolmogorov-Smirnov test, the control cells showed a significant
Figure 3. Chromosome 16 juxtacentromeric heterochromatin: area measurements in ICF cells and controls. Measurements of the areas
occupied by chromosome 16 juxtacentromeric heterochromatin, as defined by hybridisation with the D16Z3 classical satellite DNA probe, were
obtained in hundreds of 2D-fixed interphase nuclei per cell line and the mean values calculated. The measurements were performed as described in
the Materials and Methods. The data sets were compared using a Kolmogorov-Smirnov test and no statistically significant difference was observed
between ICF patients and Controls altogether (D=0.1029, P=0.076).
doi:10.1371/journal.pone.0011364.g003
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after treatment with 5-azacytidine (D=0.1697, P,0.001). How-
ever, the area of chromosome 1 juxtacentromeric heterochromatin
is significantly smaller in non-treated ICF cell lines than 5-
azacytidine treated control cell lines (D=0.2601, P,0.001). There
was also a significant difference in the areas of chromosome 1
juxtacentromeric heterochromatin between treated and non-
treated ICF cell lines (D=01341, P=0.001).
To investigate whether 5-azacytidine could also affect the
positioning of the heterochromatin within the nuclear space, the
average distance of chromosome 1 juxtacentromeric regions from
the extreme nuclear periphery was measured and compared
before and after treatment with 5-azacytidine. Measurements were
carried out as described previously (Table 2). There was no
significant difference between treated and non-treated ICF cell
lines (D=0.0708, P=0.186) and no significant difference between
the treated and non-treated control cell lines (D=0.0727,
P=0.98). However, the statistically significant difference in the
distance of chromosome 1 juxtacentromeric heterochromatin from
the extreme nuclear periphery previously observed when compar-
ing ICF and control cells was maintained even after treatment of
the control cells with 5-azacytidine (D=0.1020, P=0.009).
Figure 4. Chromosome 1 juxtacentromeric heterochromatin: volume measurements in ICF cells and controls. The nuclear volumes
occupied by the chromosome 1 juxtacentromeric heterochromatin, as defined by hybridisation with the D1Z1 classical satellite DNA probe (red) on
3D-fixed interphase nuclei (immunostained with anti-Lamin B, green), were measured and compared in ICF Patient 1 and Control 1 as described in
the Materials and Methods. The heterochromatin was shown to occupy on average a smaller volume in ICF cells. The data sets were compared using
a Kolmogorov-Smirnov test, which revealed a statistically significant difference between the ICF and Control volume distributions (D=0.2356,
P,0.001). Examples of variable heterochromatin patterns as observed by 3D-FISH, confocal analysis and volume reconstruction are shown in the top
panels.
doi:10.1371/journal.pone.0011364.g004
Nuclear Organisation in ICF
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11364Comparative analysis of the nuclear architecture parameters
used so far in our investigation, carried out in different cell lines
before and after treatment with the global demethylating agent 5-
azacytidine, shows a less conspicuous, but still significant
remodelling of chromosome 1 juxtacentromeric heterochromatin,
resulting in an altered configuration of this genomic region in both
metaphase and interphase similar to what observed in ICF cells. In
contrast, positioning of the heterochromatin in relation to the
nuclear periphery seems unaffected by the demethylating
treatment.
Analysis by quantitative PCR identifies significant
differences in the amount of classical satellite DNA
between the different cell lines
To compare the abundance of the two classical satellite DNA
families comprising the bulk of the chromosome 1 juxtacentro-
meric heterochromatin, Real Time PCR experiments with
chromosome 1-specific satellite 2 and 3 primers were carried out
in ICF cells and controls (Table 3). ICF Patient 1 has about thirty
times less satellite 2, and two times less satellite 3 than Control 1.
However, when compared to the unrelated control D0208915,
ICF patient 1 seems to have two times less satellite 2, but no
significantly different amount of satellite 3. ICF Patient 2 has two
times less satellite 2 than Control 2, but eleven times more than the
unrelated control D0208915. For the satellite 3, there is no
significant difference between ICF Patient 2 and either control.
While the abundance of the classical satellite 3 appears more or
less constant, the marked inter-individual differences observed for
the classical satellite 2 are consistent with the length-polymorphism
of this repetitive DNA family and heteromorphism of the
juxtacentromeric heterochromatin. We show that both ICF
patients present less satellite 2 repeats than their relative controls.
However, either combining the two satellites results or considering
them individually, our results show no statistically significant
correlation between satellite DNA abundance and heterochroma-
tin areas measurements in interphase (Pearson Product-Moment
Correlation combined: R=0.411 P=0.49; Satellite 2 R=0.43,
P=0.47; Satellite 3 R=20.206, P=0.74 respectively).
Analysis by Real Time RT-PCR confirms altered expression
of BTG2, CNN3, ID3, RGS1 and F13A1 in ICF
Real-time RT-PCR was performed to compare the relative
expression levels of four genes from chromosome 1 (BTG2, CNN3,
ID3, RGS1) and one gene from chromosome 6 (F13A1) in the cell
lines under investigation. Relative gene expression of the above
genes was compared between ICF Patient 1 and Control 1, and
ICF Patient 2 and Control 2. b-actin was used as a normalisation
gene. The results are summarised in Table 4. Our Real-time RT-
PCR results show altered gene expression in ICF cells, more
specifically up-regulation of CNN3, RGS1 and F13A1 and down-
regulation of BTG2 and ID3.
Analysis by MALDI-TOF mass spectrometry reveals no
significant methylation differences in CpG islands of
gene promoters between ICF and controls
DNA methylation analysis of CpG islands in the promoter
region of three of the genes under investigation, more precisely
BTG2, CNN3 and ID3, was performed to examine whether altered
expression in ICF cells may have been caused by changes in
promoter methylation. No CpG islands are present in the
promoters of RGS1 and F13A.
The analysis was performed on bisulfite treated DNA from ICF
Patient 1 and 2, Control 1 and 2, and DO208915 cell lines using a
sequencing by fragmentation assay for quantitative methylation
analysis [27]; this assay is based on RNA transcription and base -
specific cleavage. Multiple CpG sites can be detected in a single
experiment and altered methylation is detected as a G/A change
on the reverse strand. The results for all three genes show that
there are no significant differences in overall promoter CpG island
methylation between ICF cells and controls. At all CpG sites
analysed, very low and comparable levels of methylation were
Figure 5. Heterochromatin configuration at different stages of the cell-cycle. BrdU pulse labelling (green), to visualise cells undergoing
DNA synthesis (S phase), was used in conjunction with FISH with the D1Z1 probe (red) to identify a possible connection between the observed
variability in the configuration of chromosome 1 juxtacentromeric heterochromatin and progression through the cell-cycle. Comparative tests were
conducted in both ICF and controls. No differences were observed in the heterochromatin organisation when comparing B-cell nuclei in both ICF and
control cells, with ‘‘conventional’’ (A) and ‘‘compact’’ (B) hybridisation patterns equally present in non-S phase and the various stages of the S phase
of the cell-cycle. Examples above belong to a miscellanea of informative pictures collected from both ICF and control cells. S phase progression
patterns as described in O’Keefe [23].
doi:10.1371/journal.pone.0011364.g005
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summarised in the EpiGrams for each gene (Figure S4).
These results show that up-regulation of CNN3 and down-
regulation of BTG2 and ID3 are not linked to obvious changes in
the DNA methylation of their promoters.
Intra-nuclear positioning of abnormally expressed genes
and co-localisation with juxtacentromeric
heterochromatin
The association of the above genes with the extreme nuclear
periphery and relative positioning to the chromosome 1
juxtacentromeric heterochromatin were assessed by co-hybridising
each of the four BAC clones, containing the chromosome 1 genes
BTG2, CNN3, ID3 and RGS1, with the classical satellite DNA
probe D1Z1 to interphase nuclei obtained from ICF patient and
control B-lymphoblastoid cells. A BAC clone containing the
chromosome 6 gene F13A1 was also co-hybridised with D1Z1 as
well as with the chromosome 6 alpha satellite DNA probe D6Z1
and the chromosome 16 classical satellite 2 DNA probe D16Z3.
These were control experiments designed to respectively identify:
(a) possible involvement of chromosome 1 juxtacentromeric
heterochromatin in inter-chromosomal associations, (b) similarity
of behaviour in terms of inter-chromosomal gene-heterochromatin
associations between chromosome 1 and 16, and, (c) intra-
chromosomal associations involving a chromosome not specifically
affected by molecular and cytological changes in ICF syndrome.
Association of each gene with the extreme nuclear periphery
was compared in ICF Patient 1 and Control 1, and ICF Patient 2
and Control 2. A signal was considered to be positioned at the
extreme nuclear periphery if any part of it appeared to associate
with the nuclear rim, as defined by the edge of the DAPI staining.
A minimum of 250 observations were carried out per probe per
cell line (Figure 10).
For three of the genes under investigation, BTG2 and ID3 from
chromosome 1 and F13A1 from chromosome 6, the degree of
association of each locus with the extreme nuclear periphery was
practically negligible in both ICF cells and controls. The other two
genes from chromosome 1 - CNN3 and RGS1 - showed a higher
percentage of peripheral location, although, as before, no
preferential positioning at the extreme nuclear periphery were
evident for either loci. Statistical analysis confirmed that the intra-
nuclear positioning of all genes analysed, as defined by association
with the extreme nuclear periphery, is not altered in ICF cells as
the differences between ICF and controls are not significant when
using a Chi-squared test (x
2=1.042, P=0.307 for BTG2;
Figure 6. Association of chromosome 1 and 16 juxtacentromeric heterochromatin with the extreme nuclear periphery. Preferential
positioning of the chromosome 1 (A) and chromosome 16 (B) juxtacentromeric heterochromatin at the nuclear periphery was assessed in ICF Patient
1 and 2, Control 1 and 2, and DO208915. The heterochromatic signals were considered to be positioned at the extreme nuclear periphery if any part
of them appeared to associate with the nuclear rim, as defined by the edge of the DAPI staining. Panels C, D and E respectively show examples of
nuclei where none or either one or both chromosome 1 heterochromatic areas (D1Z1 signal in red) map at the extreme nuclear periphery (as
indicated by the white arrows). The reduction in association of the D1Z1 and D16Z3 hybridisation signals with the extreme nuclear periphery in ICF B-
cell lines compared to controls is in both cases statistically significant using a Chi-squared goodness of fit test, respectively (x
2=4.882, P=0.027) and
(x
2=10.563, P=0.001).
doi:10.1371/journal.pone.0011364.g006
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2=0.314, P=0.575 for CNN3; x
2=1.010, P=0.315 for ID3;
x
2=1.786, P=0.181 for RGS1; x
2=1.010, P=0.315for F13A1).
The positioning of the four genes from chromosome 1, BTG2,
CNN3, ID3 and RGS1, in relation to chromosome 1 heterochro-
matin was also analysed. Co-localisation was assessed by
identifying on cells of ICF Patient 1 and Control 1, and ICF
Patient 2 and Control 2, gene signals that showed any degree of
overlap with the satellite DNA signal. The co-localisation
assessment was carried out independently from the heterochro-
matin spatial configuration and the intra-nuclear positioning of
both gene and heterochromatic signals (Fig. 11). A minimum of
250 observations were carried out per probe per cell line
(Figure 10).
BTG2 and ID3, the two genes from chromosome 1showing low
association with the extreme nuclear periphery, are also
characterised by a comparably low extent of co-localisation with
the heterochromatin. On the contrary, CNN3 and RGS1, the two
genes from chromosome 1 showing a relatively higher extent of
association with the extreme nuclear periphery, are also
characterised by a relatively higher extent of co-localisation with
the heterochromatin.
For the two down-regulated genes, BTG2 and ID3, the extent of
co-localisation with chromosome 1 heterochromatin was not
significantly different between ICF cell and controls, using a Chi-
squared test (x
2=0.709, P=0.400 for BTG2 and x
2=0.260,
P=0.610 for ID3). However, the extent of co-localisation for
CNN3 and RGS1, the other two genes from chromosome 1 that
appear to be up-regulated, was significantly different in ICF and
control cells (x
2=6.028, P=0.014 for CNN3 and x
2=6.775,
P=0.009 for RGS1).
Figure 7. Chromosome 1 juxtacentromeric heterochromatin positioning in relation to the extreme nuclear periphery: distance
measurements in ICF cells and controls. The average distance between the centroid of the chromosome 1 juxtacentromeric heterochromatic
signal and the extreme nuclear periphery, as defined by the edge of the DAPI nuclear staining, was calculated in unsynchronised B-lymphoblastoid
cells from ICF Patients 1 and 2, Controls 1 and 2 and DO208915. When performing a Kolmogorov-Smirnov test, the distance of chromosome 1
juxtacentromeric heterochromatin from the nuclear periphery is significantly greater in ICF cell lines when compared to control cell lines (D=0.1405,
P,0.001).
doi:10.1371/journal.pone.0011364.g007
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expressed gene from chromosome 6, and both chromosome 1
and chromosome 16 juxtacentromeric heterochromatic regions
was negligible and there were no significant differences between
ICF cells and controls (x
2=0.510, P=0.475; x
2=0.000,
P=1.000). The extent of co-localisation between F13A1 and the
chromosome 6 centromeric region, as defined by hybridisation
with the alpha-satellite DNA probe D6Z1, was also assessed and
showed no statistical significance (x
2=0.122, P=0.727).
In conclusion, although the genes under investigation present a
variable extent of association with the extreme nuclear periphery,
none of them shows preferential positioning there, and, in this
respect, there are no significant differences between ICF and
control B-cells. However, in terms of co-localisation with the
juxtacentromeric heterochromatin, the inter-genic variability is
more pronounced, with two of the genes from chromosome 1 –
CNN3 and RGS1 - showing a greater extent of co-localisation with
the chromosome 1 juxtacentromeric heterochromatin. Most
importantly, for these two loci the extent of gene-heterochromatin
co-localisation is significantly reduced in the ICF cells in which
these genes appear over-regulated when compared to the control
cells.
Discussion
The complexity of ICF, in particular the combination of
phenotypic variability and genetic heterogeneity that characterises
it, has intrigued geneticists and cell biologists since this syndrome
was initially identified. Over the years, numerous and diverse
investigations have yielded interesting insights into its pathogenesis
and prompted a substantial amount of speculation on the
relationship between methylation defects, chromatin abnormalities
and clinical symptoms that characterise this complex disorder
[2,14,18,28].
Figure 8. Chromosome 16 juxtacentromeric heterochromatin positioning in relation to the extreme nuclear periphery: distance
measurements in ICF cells and controls. The average distance between the centroid of the chromosome 16 juxtacentromeric heterochromatic
signal and the extreme nuclear periphery, as defined by the edge of the DAPI nuclear staining, was calculated in unsynchronised B-lymphoblastoid
cells from ICF Patients 1 and 2, Controls 1 and 2 and DO208915. In contrast to previous observations, when performing a Kolmogorov-Smirnov test,
there is no significant difference in the distance of D16Z3 to the nuclear periphery between ICF and normal cell lines (D=0.0558, P=0.678).
doi:10.1371/journal.pone.0011364.g008
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PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11364Figure 9. Changes in chromosomal methylation patterns upon treatment with 5-azacytidine. Control cells were treated with the
demethylating agent 5-azacytidine and subsequently immunostained with a monoclonal antibody against 5-Methylcytidine (red signal). A significant
variability in terms of extent and distribution of DNA methylation within the cell populations (Control 1: A, B and C; Control 2: D, E and F) was
observed, with some metaphases and nuclei showing almost no methylation at all and others showing still substantial methylation, particularly on
the compact heterochromatic areas (white arrows). However, stretched or decondensed heterochromatin in metaphase appeared to be consistently
demethylated (white stars). Arrows and stars point specifically to chromosome 1 juxtacentromeric heterochromatin.
doi:10.1371/journal.pone.0011364.g009
Table 1. Heterochromatin configuration before and after 5-
azacytidine treatment.
Cell Line Mean Area (mm
2)S D ( mm
2)N
ICF Patient 1 (5-azacytidine) 1.17 0.47 166
ICF Patient 1 (non-treated) 1.38 0.82 322
Control 1 (5-azacytidine) 1.89 1.08 178
Control 1 (non-treated) 2.86 1.69 297
ICF Patient 2 (5-azacytidine) 1.64 0.67 163
ICF Patient 2 (non-treated) 1.78 0.75 382
Control 2 (5-azacytidine) 2.37 1.13 197
Control 2 (non-treated) 2.46 1.49 309
DO208915 (5-azacytidine) 2.02 0.87 182
DO208915 (non-treated) 2.35 0.5 262
Area measurements of chromosome 1 juxtacentromeric heterochromatin, as
defined by hybridisation with the classical satellite DNA probe D1Z1, were
carried out on cells from ICF Patients 1 and 2, Controls 1 and 2, and DO208915,
a third and unrelated control cell line, before and after treatment with the
demethylating agent 5-azacytidine (SD=standard deviation; N=total number
of measurements).
doi:10.1371/journal.pone.0011364.t001
Table 2. Heterochromatin positioning before and after 5-
azacytidine treatment.
Cell Line Distance Radius Ratio SD N
ICF Patient 1 (5-azacytidine) 4.12 10.01 0.412 2.16 208
ICF Patient 1 (non-treated) 5.24 11.39 0.460 2.90 311
Control 1 (5-azacytidine) 3.62 10.82 0.335 2.43 220
Control 1 (non-treated) 4.70 11.71 0.402 2.91 328
ICF Patient 2 (5-azacytidine) 5.53 12.55 0.441 2.70 196
ICF Patient 2 (non-treated) 4.75 9.29 0.512 2.37 358
Control 2 (5-azacytidine) 4.52 13.13 0.345 2.57 178
Control 2 (non-treated) 3.22 8.87 0.364 2.27 360
DO208915 (5-azacytidine) 4.59 14.05 0.327 2.43 201
DO208915 (non-treated) 3.77 11.18 0.337 2.62 259
The average distance between the centroid of the chromosome 1
juxtacentromeric heterochromatin signal, as defined by hybridisation with the
classical satellite DNA probe D1Z1, to the extreme nuclear periphery was
measured in cells from ICF Patients 1 and 2, Controls 1 and 2, and DO208915, a
third and unrelated cell line, before and after treatment with the demethylating
agent 5-azacytidine (Distance=Mean Distance in mm; Nuclear Radius=Mean
Nuclear Radius in mm; Ratio=Mean Distance/Nuclear Radius; SD=standard
deviation; N=total number of measurements).
doi:10.1371/journal.pone.0011364.t002
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been so far conducted predominantly on metaphase chromosomes
and, although there has been a number of observations carried out
in interphase [5,29,30,31,32,33,34,35], our study provides the first
extensive and statistically substantiated analysis on the nuclear
architecture of genes and heterochromatic regions in this
syndrome. In particular, we have examined the large-scale
organisation of chromosome 1 and chromosome 16 juxtacentro-
meric heterochromatic regions, their intra-nuclear positioning,
and their co-localisation with five specific genes, four from
chromosome 1 and one from chromosome 6, on which we have
concurrently conducted expression and methylation analysis.
These genes express proteins with different functions, ranging
from cell growth and differentiation to blood coagulation and to
association with the cytoskeleton and we selected them on the basis
of their chromosomal location, within a collection of genes
previously reported to be abnormally expressed in ICF [21]. The
investigations have been carried out in parallel in two unrelated
patients, one with Type 1 ICF and the second with Type 2 ICF,
both presenting the hypomethylation of the classical satellite 2
DNA typical of this syndrome [8]. One unrelated and two related
controls (unaffected parents of the ICF patients) have been also
included in the study.
The comparative analysis of the large-scale organisation of the
juxtacentromeric heterochromatin, undertaken by FISH analysis
on interphase nuclei, has disclosed intriguing differences between
ICF and control cells. To begin with, observations at the
microscope on a cell-by-cell basis and 2D measurements of the
areas occupied by chromosome 1 heterochromatin have revealed
that these areas were on average significantly smaller in nuclei
from the patient cell lines when compared to the controls,
suggesting an altered intra-nuclear arrangement of this specific
genomic region in ICF. These unexpected conclusions were also
confirmed by heterochromatin volume measurements obtained by
3D FISH, a cytological hybridisation procedure acknowledged to
better preserve nuclear architecture, followed by confocal analysis.
A similar reduction in the size of the heterochromatin hybridisa-
tion signals in ICF cells was also observed for chromosome 16,
although when analysed statistically the difference was shown to be
not significant.
Because of the observed inter-nuclear variability, we decided to
investigate a possible connection between heterochromatin
remodelling and progression through the cell-cycle. Based on
our FACS analysis and our results on BrdU pulse-labelled cells, we
were able to demonstrate that dissimilar percentages of different
heterochromatin configurations within each cell population cannot
be attributed to differences in cell-cycle progression.
We showed that a downsized configuration of the heterochro-
matin in interphase, similar to that observed in ICF, can be partly
reproduced in control cells by treatment with 5-azacytidine. This
demethylating agent had been previously used to reproduce in vitro
Table 3. Relative quantitation of satellite 2 and 3 using the
comparative C
t method.
Comparisons SAT2 SAT 3
Control 1 vs ICF Patient 1 28.9 2.02
D0208915 vs ICF Patient 1 2.4 Not significant
Control 2 vs ICF Patient 2 2.28 Not significant
D0208915 vs ICF Patient 2 211 Not significant
The amount of satellite 2 and 3 present in each patient is tabulated as –fold
increase with respect to different controls. Only values showing statistical
significance are shown.
doi:10.1371/journal.pone.0011364.t003
Table 4. Gene expression analysis by real-time RT-PCR.
Gene Primers Primer sequences Cell lines Fold-difference
BTG2 (1q32.1) BTG2-RT 3f/3r (59-gaaccgacatgctccc-39)( 5 9-cagtggtgtttgtagtga-39) ICF 1 vs. C 1 22.142 (p=0.001)
ICF 2 vs. C2 25.460 (p=0.013)
BTG2-RT 4f/4r (59-aataaaagccaaacct-39)( 5 9-gctttccacttttctcca-39) ICF 1 vs. C 1 22.071 (p=0.004)
ICF 2 vs. C 2 22.624 (p=0.001)
CNN3 (1p21.3) CNN3-RT 3f/3r (59-taacattacagccggtgg-39)( 5 9-aggagcagcacagtatt-39) ICF 1 vs. C 1 +2.046 (p=0.001)
ICF 2 vs. C2 +4.854 (p=0.001)
CNN3-RT 4f/4r (59-gcaattggatagaagagg-39)( 5 9-ggactcgttgaccttct-39) ICF 1 vs. C 1 +2.104 (p=0.001)
ICF 2 vs. C2 +2.019 (p=0.001)
ID3 (1p36.12) ID3-RT 4f/4r (59-caaactatgccaaggcg-39)( 5 9-cgcattgttacagaaagtca-39) ICF 1 vs. C1 22.432 (p=0.012)
ICF 2 vs. C 2 22.556 (p=0.001)
RGS1 (1q31.2) RGS1-RT 3f/3r (59-acagatagtatcaagcgca-39)( 5 9-gcgcctggataactttc-39) ICF 1 vs. C1 +2.847 (p=0.001)
ICF 2 vs. C2 +4.512 (p=0.004)
RGS1-RT 4f/4r (59-aagcgcagaaggaatg-39)( 5 9-gcgcctggataactttca-39) ICF 1 vs. C1 +2.898 (p=0.001)
ICF 2 vs. C2 +2.107 (p=0.005)
F13A1 (6p25.1) F13A1-RT 1f/1r (59-cgtcaacctgcaagag-39)( 5 9-cgaccaatgacgtattcc-39) ICF 1 vs. C1 +1.472 (p=0.001)
ICF 2 vs. C 2 +3.517 (p=0.001)
F13A1-RT 1f/2r (59-cgtcaacctgcaagag-39)( 5 9-acatagaaagactgccct-39) ICF 1 vs. C 1 +5.378 (p=0.009)
ICF 2 vs. C2 +2.843 (p=0.001)
A relative expression study for genes BTG1, CNN3, ID3, RGS1 and F13A1 in ICF patients versus controls was performed using Real-Time Reverse-Transcription PCR (RT-
PCR). Relative expression levels of genes between ICF patients and controls were calculated using the equation described in Materials and Methods.
doi:10.1371/journal.pone.0011364.t004
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syndrome [24,25,26]. Our results provide for the first time
evidence that hypomethylation of classical satellite DNA sequenc-
es, as well as contributing to promote the abnormal chromatin
structure of the juxtacentromeric regions in metaphase previously
described in these patients [8], also affects the large-scale
organisation of the same heterochromatic regions in interphase.
Our unexpected findings of an apparently more compact
configuration of the chromosome 1 juxtacentromeric heterochro-
matin in ICF B-cell nuclei do not concur with the consensus –
based on the generally acknowledged parallel between DNA
methylation and chromatin compaction [rev. in [36,37]] and also
supported by earlier observations on ICF cells [29,34] - that
decondensation and stretching of the heterochromatin, as
observed in metaphase, should also be expected in interphase.
However, we feel confident with the extent and variety of our
investigations and the robust statistical analysis that supports our
findings. Interestingly, the canonical view of a direct correspon-
dence between methylation and chromatin condensation has also
been challenged by Gilbert and co-authors. [38], who, by using
mutant mouse embryonic stem cells completely lacking in DNA
methylation, have recently shown that chromatin compaction, as
assayed by nuclease digestion and sucrose gradient sedimentation,
is not affected in these cells, their results underlining the
complexity of the relationship between DNA methylation and
chromatin structure.
Because of the intrinsic resolution limits of the microscopy
techniques and the recurring concerns in the field of chromosome
biology on the effects of cell fixation on the ‘‘live’’ properties of the
chromatin fibres in the nucleus, in particular in 2D FISH
procedures [39], we are aware that any attempt to explain the
observed altered arrangement of the juxtacentromeric heterochro-
Figure 10. BTG2, CNN3, ID3 RGS1 and F13A1: Association with the extreme nuclear periphery and the juxtacentromeric
heterochromatin. Two-colour FISH using separate probes to identify the gene and the juxtacentromeric or centromeric heterochromatin was
performed on quiescent cells from ICF patient 1 and Control 1, and cycling cells from ICF Patient 1 and 2 and Control 1 and 2. Two parameters were
investigated; the association of the gene with the extreme nuclear periphery and the association of the gene with heterochromatin. From left to
right, the graph shows the association of BTG2, CNN3, ID3, RGS1 and F13A1 with the extreme nuclear periphery in ICF cells and controls (shaded bars),
and association with chromosome 1 juxtacentromeric heterochromatin (D1Z1) in ICF and controls (white bars). The association of F13A1 with
chromosome 6 centromeric heterochromatin (D6Z1) and chromosome 16 juxtacentromeric heterochromatin (D16Z3) in ICF cells and controls is also
shown in the right-most four columns of the graph. A minimum of 250 observations were carried out for each experiment. The extent of co-
localisation for CNN3 and RGS1 with the chromosome 1 juxtacentromeric heterochromatin was found to be significantly different when comparing
ICF and control cells (x
2=6.028, P=0.014 for CNN3 and x
2=6.775, P=0.009 for RGS1).
doi:10.1371/journal.pone.0011364.g010
Figure 11. Gene-heterochromatin co-localization assessment.
Co-localisation was assessed by identifying gene signals (green)
showing any degree of overlap with the classical satellite DNA signal
(red). The co-localisation assessment was carried out independently
from the heterochromatin spatial configuration (‘‘conventional’’ in A
and B, and ‘‘compact’’ in C and D) and the intra-nuclear positioning of
both gene and heterochromatic signals.
doi:10.1371/journal.pone.0011364.g011
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speculate that the downsizing of the heterochromatin signal could
be partly the effect of a collapse in the folding of the chromatin
fibre caused by changes in the steric properties of the
hypomethylated satellite DNA and the resulting destabilization
of the chromatin structure, probably rendered more obvious by
the fixation procedures.
While investigating the altered heterochromatin organisation in
ICF, a possible linkage with the heteromorphism of the
heterochromatin deserves also consideration, as the downsizing
of the heterochromatic signal in interphase in ICF cells could
simply occur as the result of a substantial reduction in the number
of their classical satellite repeats. An interesting study by Blasco
and collaborators [40] has reported a reduction in centromeric
repeats in mouse cells lacking the Dnmt3a and Dnmt3b DNA
methyltransferases, suggesting DNA methylation at the centro-
meric heterochromatin to be an important mechanism to suppress
‘‘illicit’’ centromere mitotic recombination and to maintain
centromere integrity. The hypothesis that a variation in the
amount of juxtacentromeric heterochromatin repeat DNA or
satellite DNA length polymorphism may underlie the phenotypic
variability observed in ICF was formulated by Luciani and co-
authors in the context of their investigations on HP1 sub-cellular
distribution in ICF [30]. However, they speculated the presence of
longer stretches of 1q or 16q repeats in the disorder.
The analysis of the classical satellite DNA that we carried out by
quantitative PCR has indeed confirmed marked inter-individual
dissimilarities and a significant difference in enrichment of classical
satellite 2 repeats in ICF patients when compared to their controls,
with both patients showing fewer classical satellite 2 DNA repeats
than their respective controls. However, our analysis has also
highlighted the absence of a direct correlation between satellite
DNA length-polymorphism and heterochromatin configuration.
Taken all together, our observations point towards an intermedi-
ate scenario in which both DNA hypomethylation and differences
in the copy number of classical satellite sequences contribute to the
altered spatial organisation of the juxtacentromeric heterochro-
matin in ICF.
Having established the existence of consistent and quantifiable
differences in the large-scale organisation of the juxtacentromeric
heterochromatin in ICF, we proceeded to investigate possible
changes in the intranuclear positioning of this genomic region in
this syndrome, using as a spatial reference the extreme periphery.
Although its role in actively regulating gene expression remains
unproven, the nuclear periphery is generally considered a
transcriptionally silent ‘‘address’’ within the nuclear volume,
characterised in yeast by the high concentration of silencing sir
proteins [41] and in higher eukaryotes by poor gene density
[42,43,44] and high concentration of non-transcribed sequences
[45]. Also, repositioning of silent genes from the nuclear interior to
the nuclear periphery has been observed in few instances
[46,47,48,49].
Our measurements of the distance between chromosome 1
heterochromatin and the nuclear rim have revealed that the extent
of association with the nuclear periphery is reduced in ICF B-cells,
suggesting a specific re-positioning of this genomic region to a
more internal location within the nuclear space. Based on the
differential distribution of early and late-replicating chromatin
within the nucleus [50,51], our findings on the relocation of the
heterochromatin away from the extreme nuclear periphery to a
more internal position agree with the advanced replication of the
hypomethylated satellite 2 previously reported in ICF [8].
Evidence for a similar repositioning of the chromosome 1
juxtacentromeric heterochromatin within the nuclear volume,
following treatment with the histone deacetylase inhibitor
trichostatin A (TSA), was published before [52].
Our findings on the altered large-scale organisation and intra-
nuclear positioning of chromosome 1 juxtacentromeric hetero-
chromatin in ICF are particularly significant in the light of the
mounting experimental evidence suggesting chromosome band
1q12 to be the core of a nuclear domain with functional
significance, with earlier investigations showing physical associa-
tion of this genomic region with the human polycomb group
complex [53], and also with the oncogenic transcriptional
regulator TLX1/HOX11 in leukemic T-cells [54]. In ICF cells
the 1qh satellite DNA is associated in G2 with a giant HP1-PML
nuclear body [31].
Inordertoexplorethe existenceofa possiblelink between altered
heterochromatin organisation and changes in gene expression in
ICF, we investigated the intra-nuclear positioning of four specific
genes from chromosome 1 (BTG2, CNN3, ID3 and RGS1), using as a
spatial reference their association with the extreme nuclear
periphery, as well as their co-localisation with chromosome 1
heterochromatin.Thegeneswereselected from acollectionofgenes
previously reported to be abnormally expressed in ICF [21]. We
were also interested in identifying possible long-range interchro-
mosomal gene-heterochromatin associations, therefore we included
in the analysis F13A1, a gene mapping on 6p25-24, also previously
reported to be abnormally expressed in ICF [21]. In parallel to the
cytological investigations, relative gene expression analysis was
carried out by Real Time RT-PCR. Our experiments showed
comparative up-regulation of CNN3, RGS1 and F13A1 and down-
regulation of BTG2 and ID3 in our ICF cell lines, confirming
previous results obtained by microarray analysis [21].
We also tested for a direct role of methylation on gene
expression changes by carrying out a comparison of CpG islands
in the promoter regions of three of the genes under examination,
namely CNN3, BTG2 and ID3. Our methylation analysis, carried
out by base-specific cleavage and mass spectrometry, established
that the genes were largely unmethylated and detected no
significant changes in ICF cells. The promoter regions of RGS1
and F13A1, the other two genes under investigation not included
in our methylation analysis due to the absence of CpG islands in
their promoters, had previously shown no ICF-linked changes in
the overall promoter methylation [21].
In terms of nuclear positioning, our observations show two of
the genes analysed – RGS1 and CNN3 – to be not exclusively, but
more frequently associated with the extreme nuclear periphery
than the other three genes under investigation, for which the
degree of association with the nuclear rim was negligible.
However, no significant differences were observed when the
positioning of each of the genes in relation to the extreme nuclear
periphery was compared between ICF cells and controls.
Results that are more relevant were provided by our analysis of
genes and chromosome 1 juxtacentromeric heterochromatin co-
localisation, as RGS1 and CNN3, the two up-regulated genes from
chromosome 1, showed a significant reduction in their extent of
co-localisation with juxtacentromeric heterochromatin in ICF
nuclei when compared to controls. Correlation between gene
silencing and localisation to transcriptionally repressive hetero-
chromatic compartments has been reported in mouse cycling
lymphocytes [55,56,57], human and mouse erythroid cells
[58,59,60] and retinoblastoma cells [61]. More recently, a link
between centromeric recruitment and establishment of allelic
exclusion at the immunoglobulin heavy-chain gene in mouse B-
cells was also reported [62]. Therefore, it is conceivable that RGS1
and CNN3 are normally silenced in B-cells through association
with the heterochromatin and this association is disrupted in ICF.
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extent of co-localisation between chromosome 1 juxtacentromeric
heterochromatin and BTG2 and ID3, the two genes showing
down-regulation in ICF but no significant changes in promoter
CpG islands methylation, was negligible and there were no
significant differences between ICF cells and controls. These
findings solicit further investigations into different aspects of
nuclear architecture and other possible epigenetic mechanisms
likely to affect the regulation of these two genes.
In conclusion, we suggest that in ICF the length and
hypomethylation of the classical satellite 2 DNA, the main
component of the juxtacentromeric heterochromatin of chromo-
somes 1,and 16, are not only responsible for the centromeric
abnormalities generally observed in metaphase, but also affect the
three-dimensional organisation of the heterochromatin in inter-
phase. This is based on our findings – partly reproducible in
control cells by demethylating treatment - that in ICF B-cell nuclei
the chromosome 1 juxtacentromeric heterochromatin appears
significantly smaller in volume and more internally positioned
within the nuclear space. On the basis of our observations on the
changes in the extent of co-localisation of two up-regulated genes
(CNN3 and RGS1) and chromosome 1 juxtacentromeric hetero-
chromatin, we also postulate that, by affecting long-range gene-
heterochromatin associations, the altered intra-nuclear arrange-
ment of the hypomethylated classical satellite sequences interferes
with heterochromatin mediated gene silencing and contributes to
some of the changes in gene expression observed in ICF.
Our findings support earlier suggestions of an epigenetic impact
of chromatin and chromosomal changes in ICF syndrome and
present an example of how human diseases can provide ideal
model systems to investigate the functional significance of nuclear
architecture.
Materials and Methods
Cell lines
The ICF B-lymphoblastoid cell line GM08714A, and a control
cell line generated from the patient’s mother, GM08728, were
obtained from the Coriell Cell Repositories (USA) http://ccr.
coriell.org/. A second ICF B-lymphoblastoid cell line, LB188, and
a control cell line from the patient’s mother, LB290, had been
previously established and described [63]. An additional control
cell lines used for the study was the B-lymphoblastoid cell line,
DO208915 (European Collection of Cell Cultures, UK). For
simplicity purposes, in the paper the ICF cell line GM08714A is
referred to as ICF patient 1 and the ICF cell line LB188 as ICF
patient 2. The control cell line GM08728 is referred to as Control
1, and LB290 as Control 2. ICF patient 1 is a compound
heterozygote for mutations in DNMT3B, carrying a G.A
transition at nucleotide 1807 on one allele, and a G.A transition
within intron 22, 11 nucleotides 59 of a splice acceptor site on the
other allele, and has Type 1 ICF syndrome. ICF patient 2 does not
carry a mutation in DNMT3B and has Type 2 ICF syndrome.
Data on the hypomethylation of satellite 2 in both patient cell lines
can be found in Hassan et al. 2001 [8] (wherein GM08714 is
referred to as PT4 and LB188 is referred to as PT12).
Cell culture and slides preparation
Cells were cultured in suspension in RPMI-1640 medium
(Sigma-Aldrich, UK) supplemented with 10% foetal bovine serum
(Sigma-Aldrich) and 1% L-Glutamine at 37uC in a 5% CO2
incubator. Slow-growing cultures, enriched in G0/G1 cells, were
obtained by incubating the cells with no serum for 72 hours. For
cell-cycle investigations, cells were pulse-labelled with 10 mM5 -
Bromo-2-deoxyuridine (BrdU) (Sigma-Aldrich) for 30 minutes
prior to cell harvesting. For the demethylating agent treatment,
5-azacytidine (Sigma-Aldrich) was added to the cell cultures at a
final concentration of 0.5 mM followed by incubation at 37uC for
18 hours, a wash and incubation in normal conditions for
72 hours prior to cell harvesting, as previously described [25].
To obtain metaphase chromosomes, thymidine (Sigma-Aldrich)
was added to each culture at a final concentration of 0.3 mg mL
21
and incubated at 37uC for 17 hours. 10 minutes prior to harvest,
Colcemid (Invitrogen, UK) was added at a final concentration of
0.2 mgm L
21. The cells were centrifuged, resuspended in
prewarmed hypotonic solution (0.075 M potassium chloride) for
5 minutes and fixed in three changes of 3:1 methanol: acetic acid.
Slides were prepared according to standard procedures. Meta-
phase chromosomes obtained from cultures treated with 5-
azacytidine were harvested without thymidine. For interphase
preparations no thymidine or Colcemid were used. For 3D FISH
analysis, cells were resuspended in 16PBS at a density of 2610
6
cells mL
21. 200 mL of the cell suspension was pipetted onto a poly-
lysine coated slide (VWR International, UK) and the slide
incubated in a moist chamber for 1 hour at 37uC. Following
incubation, the slides were processed by washing in 16PBS on ice
for 5 minutes and then in CSK/TX (0.1 M NaCl; 0.3 M Sucrose;
0.003 M MgCl2; 0.01 M Pipes; 0.5% Triton X-100). The cells
were fixed in 4% formaldehyde/16 PBS for 5 minutes at room
temperature, washed in 16PBS and permeabilised in 0.5% Triton
X-100/16 PBS for 20 minutes at room temperature. The slides
were again washed in 16PBS and then incubated in 0.1 M HCl
for 10 minutes at room temperature. After a final wash in 16PBS,
the slides were stored in 70% ethanol.
Probes
BAC clones containing genes BTG2 (RP11-134p9), CNN3 (RP4-
639p13), ID3 (RP1-150o5) and RGS1 (RP5-1011o1) were obtained
from the Sanger Institute (Cambridge, UK). A DNA preparation
of the BAC containing gene F13A1 (287k15) was obtained directly
from the Genomics Core Group, Wellcome Trust Centre for
Human Genetics, Oxford. BAC DNA extraction was carried out
according to standard procedures. Prior to FISH analysis, the
BAC clones were verified for gene content by Polymerase Chain
Reaction (PCR) amplification. The primers (Table S1) were
generated using ‘‘Primer 3’’ design software (http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3_www.cgi) based on the genomic
sequences of BTG2, CNN3, ID3 and RGS1 obtained from the
Human Genome Browser Gateway (http://genome.ucsc.edu/cgi-
bin/hgGateway?org=human). Primers were synthesised by
MWG Biotech (Germany). Directly labeled chromosome 1
classical satellite probe (D1Z1) (Qbiogene, UK) and chromosome
16 satellite 2 DNA probe (D16Z3) (Abbott Laboratories, UK) were
used to visualise the juxtacentromeric heterochromatin. The
chromosome 6 alpha satellite probe (D6Z1) (Qbiogene) was also
used.
Fluorescence in situ hybridisation (FISH)
80 ng of probe DNA - labeled with biotin-11-dUTP (Roche)
using a nick-translation kit (Abbott Laboratories) - and 2 mgo f
human C0t-1 competitor DNA (Invitrogen) were dried on a
heating block at 65uC and resuspended in 16hybridisation buffer
(50% formamide, 16 SSC and 10% dextran sulphate) to a final
concentration of 16 ng mL
21. Prior to hybridisation, the probes
were denatured at 72uC for 10 minutes and pre-annealed at 37uC
for 30 minutes. The chromosome 1 classical satellite probe
(D1Z1), chromosome 16 satellite 2 DNA probe (D16Z3) and
chromosome 6 alpha-satellite (D6Z1) probe were denatured at
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hybridisation. The slides were denatured in 70% formamide/0.66
SSC at 70uC for 2 minutes. Following hybridisation, in a moist
chamber at 37uC overnight, the slides were washed in 50%
formamide/16SSC at 42uC for 10 minutes and 26SSC at 42uC
for 5 minutes. The biotinylated probes were detected with a layer
of streptavidin conjugated FITC (Vector Laboratories, UK) when
co-hybridised with red-labelled heterochromatin probes, or
streptavidin-Texas Red (Invitrogen) when used with green
heterochromatin probes. Slides were mounted with Vectashield
(Vector Laboratories) containing 49, 6-diamidino-2-phenylindole
(DAPI) for nuclear staining. Prior to FISH, the BrdU pulse-
labelled cells were treated with 0.5% Triton X-100 in 16PBS for
10 minutes and then transferred to 0.1 M hydrochloric acid for
10 minutes at room temperature. The slides were then washed in
26SSC for 5 minutes and then equilibrated in 50% formamide/
26 SSC for at least 15 minutes prior to denaturation. BrdU
labelling was detected using mouse anti-BrdU antibody (Roche) in
4% BSA in 16PBS/0.1% Tween-20 and incubated at 37uC for
30 minutes. This was detected using goat anti-mouse Alexa 488
(Invitrogen). Slides were mounted with Vectashield containing
DAPI.
Immunofluorescence
Metaphase slides were denatured in 65% formamide, 26SSC at
65uC for 309, then dehydrated in ethanol series, and air-dried. The
slides were then briefly washed in 26SSC and incubated with
blocking solution (1% non-fat dried milk in PBS/0.1% Tween-20)
at 37uC. After 30 minutes a monoclonal antibody against 5-
Methylcytidine (Eurogentec) (diluted 1:100 in PBS/0.1% Tween-
20) was applied to the samples and the slides were then incubated
for 2 hours. The slides were finally washed in PBS three times for
10 minutes and incubated with a secondary antibody, Texas Red
goat-anti mouse (Sigma) for 30 minutes. Slides were mounted with
Vectashield containing DAPI.
Image acquisition and analysis
FISH experiments were examined with a 1006, 1.3 NA oil-
immersion objective lens fitted to an Olympus BX-51 epifluores-
cence microscope coupled to a Sensys charge-coupled device
(CCD) camera (Photometrics, USA). Blue, green and red
fluorescence images were taken as separate grey-scale images
using the 83000 filter set manufactured by Chroma (USA) and
then pseudo-coloured and merged using the software package
Genus (Applied Imaging International, UK). Grey-scale images of
the heterochromatin taken with Genus were imported into
Volocity (Improvision, UK), and an image series created for each
experiment. Using the Classifier feature, the areas of juxtacen-
tromeric heterochromatin were measured using the percentage
mode empirically set to a lower limit of 27% intensity, an upper
limit of 100%, and to exclude areas smaller than 25 pixels and
larger than 500 pixels (examples in Figure S5). Nuclei were scored
randomly. Measurements form two independent experiments were
obtained for each cell line and the mean areas calculated.
Measurements of the volumes of D1Z1 were also obtained using
Volocity. Z stacks generated by laser scanning confocal micros-
copy (Zeiss LSM510META) were imported into Volocity, where
the Classifier feature, empirically set to threshold images at a lower
limit of 14% intensity and upper limit of 100%, measured the
volumes occupied by D1Z1 signal. Measurements of the distances
of chromosome 1 and 16 juxtacentromeric heterochromatin from
the extreme nuclear periphery were imported into the software
package Volocity and an image series generated for each
experiment. Using the VoxelSpy feature, line measurements were
taken from the centroid of the juxtacentromeric heterochromatin
signals to the extreme nuclear periphery or nuclear rim where the
intensity value became less than one standard deviation above
background. The microscope used for image capture had been
previously calibrated with a stage-micrometer and a conversion
factor of 0.135 mm pixel
21 was applied to images captured using
the 1006objective. For the varying sizes of nuclei to be taken into
account when measuring the distances of juxtacentromeric
heterochromatin from the extreme nuclear periphery, the values
were normalised between patient and control pairs. This was done
by measuring the areas of DAPI stained nuclei by the Classifier
feature in Volocity, using the percentage mode set to a lower limit
of 12% intensity, an upper limit of 100% and excluding areas
smaller than 5000 pixels. Tables of nuclear areas were exported
for processing in Microsoft Excel, and the mean nuclear radius
was calculated for each cell line. This allowed the ratios of distance
from extreme nuclear periphery to nuclear radius to be calculated.
The ratios for the ICF cell lines were 0.460 (Patient 1) and 0.512
(Patient 2). For the control cell lines, the ratios were 0.402 (Control
1), 0.364 (Control 2) and 0.337 (DO208915).
Statistical analysis of FISH data
Categorical data, such as that obtained when making
observations of association or non-association with the extreme
nuclear periphery of juxtacentromeric heterochromatin or genes,
were statistically analysed using a Chi-squared goodness of fit test.
For these analyses, observed frequencies from the ICF samples
were compared to expected frequencies, as obtained from the
controls. Quantitative data from the area, volume and distance
measurements, which demonstrate a normal distribution, were
statistically analysed using the non-parametric Kolmogorov-
Smirnov test. For Kolmogorov-Smirnov test: D=the maximum
difference between the cumulative distributions; P=probability of
the null hypothesis. A P value of #0.05 is generally accepted as
having biological significance.
Quantitative Real Time PCR
Total genomic DNA was prepared from each of the samples
using Qiagen Blood and Cell Culture DNA Mini Kit as
recommended by the manufacturer. For Real Time PCR, 50 ng
of each individual DNA were amplified using the Sybr Green kit
(Invitrogen) on an iCycler Bio-Rad (UK) Real-Time PCR system,
using the following primers: hsSat2 (NCBI accession number
X72623) 59-ATCGAATGGAAATGAAAGGAGTCA-39;5 9-GA-
CCATTGGATGATTGCAGTCA-39. S1/AS1 [64] 59-AGTC-
CATTCAATGATTCCATTCCAGT-39;5 9-AATCATCATC-
CAACGGAAGCTAATG-39.
As a reference, primers for a single copy gene, CENPB (NCBI
accession number NP 001801), 59-GGCTTACTTTGCCAT-
GGTCAA-39 59-TTGATGTCCAAGACCTCGAACTC-39 and
Alu sequences (NCBI accession number D90162) were used.
59-CTCCCGGATTCAAGCAATTA-39
59-CATGGTGAAACCCCATCTCT-39
In each experiment, for each DNA sample, five replicates were
run.
The Ct values were compared using the 2
2DDCT formula.
Gene expression analysis by Real-Time RT-PCR
Total RNA was extracted from B-lymphoblastoid cells from
ICF patient 1 and 2, and Control 1 and 2 using the RNeasy
extraction kit (Qiagen, UK) as recommended by the manufactur-
er. Reverse transcription reactions were performed to generate
2 mg of cDNA from 2 mg of total RNA. First strand synthesis was
set up by adding 500 mg of Oligo(dT) (Invitrogen), 10 mM dATP,
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RNA and incubating at 65uC for 5 minutes before chilling on ice
for 5 minutes. 56first stand buffer, 0.1 M DTT and 40 units of
RNaseOUT
TM (Invitrogen) were added to the reactions, which
were incubated at 42uC for 2 minutes. 200 units of SuperScript
TM
II reverse transcriptase (Invitrogen) were added and the reactions
incubated at 42uC for 50 minutes, before inactivation at 70uC for
15 minutes. The relative expression of BTG2, CNN3, ID3, RGS1
and F13A1 in ICF patient and control cell lines was analysed using
the Bio-Rad iCycler system. Reactions were set-up with 100 ng of
template cDNA, 500 nM primers and iQ SYBR Green PCR
Supermix (Bio-Rad). b-actin was used as a normalisation gene.
Primers suitable for real-time RT-PCR (Table S1) were designed
with the LightCycler (Roche) primer design software using mRNA
sequences of the genes obtained from the Human Genome
Browser Gateway. Relative gene expression was calculated using
the following formula [65]:
R~
Etarget
 CPtarget MEANcontrol{MEANsample ðÞ
Eref ðÞ
CPref MEANcontrol{MEANsample ðÞ
R=Relative expression ratio
E=Efficiency of PCR (calculated from E=10
(21/slope of optimisation curve))
MEAN=Normalisation gene
CP values were obtained from the Bio-Rad iCycler software
when viewing post-run data
Quantitative methylation analysis
Genomic DNA was extracted from B-lymphoblastoid cells from
ICF patient 1 and 2, Control 1 and 2, and DO208915 using the
GeneCatcher
TM gDNA 3–10 mL Blood Kit (Invitrogen). 1 mgo f
genomic DNA was denatured and bisulfite treated using the EZ
DNA Methylation-Gold Kit (Zymo Research, USA). Following
this treatment, PCR was performed to amplify regions from genes
BTG2, CNN3 and ID3, using 10 mM tailed primers described in
Table S2 and using Qiagen Hot Start Taq. PCR products were
then processed using the MassCLEAVE kit reagents from
Sequenome (San Diego, USA) to generate reverse strand specific
fragments for MALDI_TOF mass spectrometry [27]. Condition-
ing of the phosphate backbone prior to MALDI-TOF mass
spectrometry was performed by the addition of 6 mg of CLEAN
resin (Sequenom, San Diego, USA). 15 nL of the cleavage
reactions were robotically dispensed onto silicon chips preloaded
with matrix (Sequenom, San Diego, USA). The mass spectra were
obtained using the Autoflex MassARRAY mass spectrometer
(Sequenom, San Diego, USA) and analysed using proprietary
interpretation software tools.
Supporting Information
Figure S1 FACS analysis. Cell cycle phase composition was
analysed by FACS. The four unsynchronysed cell lines present
similar percentages of diploid cells in G1, S and G2.
Found at: doi:10.1371/journal.pone.0011364.s001 (0.09 MB TIF)
Figure S2 Effects of the 5-azacytidine on Control 1 cells.
Metaphase spreads obtained from Control 1 after the demethyl-
ating treatment show variable extent of decondensation or
stretching of the chromosome 1 juxtacentromeric heterochromatin
(white arrows), similar to what normally observed in ICF cells.
Panels C, D and E show dual colour FISH images with D1Z1 in
green and D9Z3 in red. Chromosomes are counterstained with
DAPI.
Found at: doi:10.1371/journal.pone.0011364.s002 (2.08 MB TIF)
Figure S3 Effects of the 5-azacytidine on Control 2 cells.
Similarly to what observed for Control 1, metaphase spreads
obtained from Control 2 after the demethylating treatment show
variable extent of decondensation or stretching of the chromosome
1 juxtacentromeric heterochromatin (white arrows), similar to
what normally observed in ICF cells. Panels B and D show dual
colour FISH images with D1Z1 in green and D9Z3 in red.
Chromosome are counterstained with DAPI.
Found at: doi:10.1371/journal.pone.0011364.s003 (1.78 MB TIF)
Figure S4 Quantitative methylation analysis of BTG2, CNN3
and ID3. The methylation status of promoter CpG islands
upstream of genes BTG2, CNN3 and ID3 was investigated using
a MALDI-TOF based quantitative methylation assay on bisulphite
treated DNA (for details see Materials and Methods). The
EpiGrams summarise the data from the C and T specific cleavage
reactions (internal and external circle respectively), the detected
methylation level is represented as colour gradient based on the
percentage of methylation detected by the analysis. The specific
CpG sites for each gene CpG island analysed are numbered and
shown in the specific base pair position within the specific
amplicon: BTG2 (A), CNN3 (B) and ID3 (C). ICF Patients 1 and 2,
Controls 1 and 2 and additional controls of DO208915,
methylated control DNA (Chemicon, USA), hemi-methylated
control DNA obtained mixing an unmethylated and a methylated
control in equal concentration.
Found at: doi:10.1371/journal.pone.0011364.s004 (5.43 MB TIF)
Figure S5 Intra-nuclear measurements of the juxtacentromeric
heterochromatic areas on 2D fixed cells. The nuclear areas
occupied by the juxtacentromeric heterochromatic regions, as
defined by hybridisation on 2D-fixed interphase nuclei with the
corresponding classical satellite DNA probes, were measured.
Raw images were thresholded using the Classifier feature of
Volocity at a level which excluded background fluorescence with
the threshold set to a lower limit of 27% intensity, and an upper
limit of 100%. Both limits were defined empirically. Areas smaller
than 25 pixels and larger than 500 pixels were excluded. The
resulting areas, outlined in the images by a dashed line, were
measured and exported as data tables for analysis in Excel.
Examples of different hybridisation patterns: conventional (A)
versus compact (B).
Found at: doi:10.1371/journal.pone.0011364.s005 (1.14 MB TIF)
Table S1 Primer pairs used for PCR and real-time RT-PCR.
Primers used for PCR to validate the presence of the correct insert
in the BAC clones were generated from genomic sequences
obtained from the Human Genome Browser Gateway and
detailed in the table above. Primers used for quantitative
real-time reverse-transcription PCR (RT-PCR) were generated
from mRNA sequences of the genes of interest obtained from
the Human Genome Browser Gateway and are also detailed
above.
Found at: doi:10.1371/journal.pone.0011364.s006 (0.08 MB JPG)
Table S2 Primers for PCR reactions prior to quantitative
methylation analysis using the Sequenom mass spectrometer.
The sequences of the primers used to amplify the promoter CpG
islands of genes BTG2, CNN3 and ID3 and the sizes of products
expected from the PCR reactions.
Found at: doi:10.1371/journal.pone.0011364.s007 (0.04 MB JPG)
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